Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma

Abstract Group3 (G3) medulloblastoma (MB) is one of the deadliest forms of the disease for which novel treatment is desperately needed. Here we evaluate ribociclib, a highly selective CDK4/6 inhibitor, with gemcitabine in mouse and human G3MBs. Ribociclib central nervous system (CNS) penetration was assessed by in vivo microdialysis and by IHC and gene expression studies and found to be CNS-penetrant. Tumors from mice treated with short term oral ribociclib displayed inhibited RB phosphorylation, downregulated E2F target genes, and decreased proliferation. Survival studies to determine the efficacy of ribociclib and gemcitabine combination were performed on mice intracranially implanted with luciferase-labeled mouse and human G3MBs. Treatment of mice with the combination of ribociclib and gemcitabine was well tolerated, slowed tumor progression and metastatic spread, and increased survival. Expression-based gene activity and cell state analysis investigated the effects of the combination after short- and long-term treatments. Molecular analysis of treated versus untreated tumors showed a significant decrease in the activity and expression of genes involved in cell-cycle progression and DNA damage response, and an increase in the activity and expression of genes implicated in neuronal identity and neuronal differentiation. Our findings in both mouse and human patient-derived orthotopic xenograft models suggest that ribociclib and gemcitabine combination therapy warrants further investigation as a treatment strategy for children with G3MB.

[1]  David T. W. Jones,et al.  Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Roussel,et al.  Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma , 2021, Science Translational Medicine.

[3]  T. Merchant,et al.  Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Leary,et al.  A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC‐042) , 2021, Pediatric blood & cancer.

[5]  Jessica M. Rusert,et al.  Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma , 2020, Cancer Research.

[6]  N. Sanai,et al.  Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment , 2020, Clinical pharmacology and therapeutics.

[7]  M. Roussel,et al.  Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource , 2020, Acta Neuropathologica.

[8]  M. Malumbres,et al.  Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition. , 2020, Cancer cell.

[9]  Amanda R. Kulick,et al.  Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer , 2020, Cell.

[10]  Eric W Prince,et al.  Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine , 2020, Journal of Neuro-Oncology.

[11]  E. Knudsen,et al.  Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer , 2019, Oncogene.

[12]  Chiun-Sheng Huang,et al.  Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer , 2019, Clinical Cancer Research.

[13]  Nader Sanai,et al.  A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort , 2019, Clinical Cancer Research.

[14]  Volker Hovestadt,et al.  Resolving medulloblastoma cellular architecture by single-cell genomics , 2019, Nature.

[15]  S. Baker,et al.  CNS penetration of the CDK4/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors , 2019, Cancer Chemotherapy and Pharmacology.

[16]  N. Sanai,et al.  Determination of total and unbound ribociclib in human plasma and brain tumor tissues using liquid chromatography coupled with tandem mass spectrometry , 2019, Journal of pharmaceutical and biomedical analysis.

[17]  M. Roussel,et al.  Preclinical Modeling of Image-Guided Craniospinal Irradiation for Very-High-Risk Medulloblastoma. , 2019, International journal of radiation oncology, biology, physics.

[18]  Alireza Khatamian,et al.  SJARACNe: a scalable software tool for gene network reverse engineering from big data , 2018, Bioinform..

[19]  John T. Poirier,et al.  NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination , 2018, Science.

[20]  Emmanuel Barillot,et al.  Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling. , 2018, Cancer cell.

[21]  Colin J. Daniel,et al.  Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. , 2018, Cancer cell.

[22]  Jennifer L. Hadley,et al.  A Single-Cell Transcriptional Atlas of the Developing Murine Cerebellum , 2018, Current Biology.

[23]  W. Roos,et al.  Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells. , 2018, Cancer letters.

[24]  Nikolas Herold,et al.  Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism , 2018, Cancers.

[25]  M. Roussel,et al.  Mouse medulloblastoma driven by CRISPR activation of cellular Myc , 2018, Scientific Reports.

[26]  Haiyan Tan,et al.  Hippo/Mst signalling couples metabolic state and immune function of CD8α+ dendritic cells , 2018, Nature.

[27]  Melissa J. Davis,et al.  Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models , 2017, Clinical Cancer Research.

[28]  A. Goldenberg,et al.  Intertumoral Heterogeneity within Medulloblastoma Subgroups. , 2017, Cancer cell.

[29]  M. Fischer,et al.  A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors , 2017, Clinical Cancer Research.

[30]  J. Ward,et al.  Application of Immunohistochemistry in Toxicologic Pathology of the Hematolymphoid System , 2017 .

[31]  G. Shapiro,et al.  A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas , 2016, Clinical Cancer Research.

[32]  G. Shapiro,et al.  Targeting CDK4 and CDK6: From Discovery to Therapy. , 2016, Cancer discovery.

[33]  J. Mesirov,et al.  DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets , 2016, Clinical Cancer Research.

[34]  S. Chen‐Kiang,et al.  CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity. , 2015, Cancer research.

[35]  Dong Ho Kim,et al.  Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience , 2014, Pediatric blood & cancer.

[36]  E. Knudsen,et al.  CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer , 2014, Oncotarget.

[37]  P. Iversen,et al.  Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine , 2014, Investigational New Drugs.

[38]  J. Olson,et al.  Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma. , 2014, Cancer cell.

[39]  R. Beroukhim,et al.  BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma , 2013, Clinical Cancer Research.

[40]  Andrew C. Wood,et al.  Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma , 2013, Clinical Cancer Research.

[41]  Steven J. M. Jones,et al.  Subgroup-specific structural variation across 1,000 medulloblastoma genomes , 2012, Nature.

[42]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas , 2012, Acta Neuropathologica.

[43]  M. Roussel,et al.  A mouse model of the most aggressive subgroup of human medulloblastoma. , 2012, Cancer cell.

[44]  W. Koch,et al.  CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy , 2012, Cell cycle.

[45]  D. Frappaz,et al.  Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study. , 2011, European journal of cancer.

[46]  Axel Benner,et al.  Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  M. Hatten,et al.  The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. , 2005, Genes & development.

[48]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[49]  C. Sherr.  Cancer Cell Cycles , 1996, Science.